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ABSTRACT
Precision medicine has been announced as a new health revolution. The term precision implies 
more accuracy in healthcare and prevention of diseases, which could yield substantial cost 
savings. However, scientific debate about precision medicine is needed to avoid wasting economic 
resources and hype. In this commentary, we express the reasons why precision medicine cannot be 
a health revolution for population health. Advocates of precision medicine neglect the limitations 
of individual-centred, high-risk strategies (reduced population health impact) and the current 
crisis of evidence-based medicine. Overrated “precision medicine” promises may be serving vested 
interests, by dictating priorities in the research agenda and justifying the exorbitant healthcare 
expenditure in our finance-based medicine. If societies aspire to address strong risk factors for 
non-communicable diseases (such as air pollution, smoking, poor diets, or physical inactivity), 
they need less medicine and more investment in population prevention strategies.
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INTRODUCTION
Precision medicine (also referred to as personalised medicine) has been proposed as the new 
route to offset the gloom-and-doom forecasts for non-communicable diseases in developed 
countries. For example, some projections indicate that cardiovascular disease rates will rise in 
USA by 10% between 2010 and 20306. The term “precision” implies more accuracy in healthcare 
and prevention of diseases, which may yield substantial health care cost savings4. This paradigm 
relies on the narrative that an ever-increasing knowledge of biological mechanisms, especially 
genetics, coupled with information technology will lead to transformative improvements 
in population health. To illustrate this, in 1999, Francis Collins envisioned a revolution in 
medicine with the Human Genome Project4. However, many of the prospects announced by 
precision medicine advocates have failed2,11,12. Epidemiologists Bayer and Galea2 recently made 
a convincing case about the limitations of precision medicine stating that health differences 
among different social groups are mainly not driven by better clinical treatments but by marked 
differences in socioeconomic factors. They have quoted the lesson learnt with the Whitehall 
studies of British civil servants, in which free healthcare did not avoid a marked social health 
gradient among groups. The case of United States is even more illustrative. Although the 
USA spends approximately 18% of its gross domestic product in health care (twice the rate 
of other rich countries), Americans attain poorer health indicators than citizens from many 
other developed economies19. Furthermore, the key idea underpinning the Human Genome 
Project and precision medicine ( for most diseases, a reduced number of common genetic 
variants may predict disease risk) has been rejected and the translation from bench to bedside 
of the genetic knowledge is highly disappointing, as no therapies have been developed to treat 
a single gene disorder, such as sickle cell anemia10. Why, then, $15 billion of the $26 billion of 
extramural research funding sponsored by the National Institutes of Health (NIH) in USA is 
precision medicine-related research (e.g., gene, genome, stem cells, or regenerative medicine)11? 
Here, we call for greater recognition of the social determinants of health in the biomedical 
community and we suggest some solutions that could help to mitigate the burden of 
non-communicable diseases worldwide.
THE PRIMARY DETERMINANTS OF HEALTH ARE SOCIOPOLITICAL
It is well established that social disadvantaged groups have a lower life expectancy and 
quality of life (disability-free life expectancy) in both high-income and low- to middle-
income countries14. In fact, as the evidence of the impact of social inequalities in health 
was robust in 2005, the World Health Organization set up the Commission on Social 
Determinants of Health to promote action14. The social gradient in health gets under the 
skin from the very early stages of life ( for a detailed information about this topic, see the 
book “The Health Gap”14). Unfortunately, policies that specifically address socioeconomic 
inequalities, improve job conditions, increase the availability of healthy foods, and empower 
individuals to follow physically active lifestyles are virtually nonexistent. In contrast, 
blue-sky research receives a disproportionately large investment with a very dynamic 
market, but with unproven, uncertain returns in terms of population health. Furthermore, 
under free market rules, “evidence”-based medicine serves different commercial agendas 
than originally intended8. Next, we illustrate with some examples the limited public health 
impact of precision medicine.
WHY INDIVIDUAL CENTRED ATTEMPTS TO CHANGE HEALTH BEHAVIOURS 
ARE INEFFECTIVE
Advocates of precision medicine claim that advances and implementation of new technologies 
will optimize prevention strategies13. However, regardless of how technologically sophisticated 
a society may evolve, citizens should be very careful with all these promises, because:
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1. An excessive emphasis in technological solutions to prevent or treat diseases diverts our 
attention from the root of the problem: health relies on favourable social circumstances14;
2. In addition, clinical medicine and “precision” prevention have become an industry 
advertisement tool8. Protecting individuals against big corporations in the current 
political scenario may sound naive given the constant economic inequalities experienced 
in the world in the last decades16. In a fair world, healthy living directly threatens many 
powerful corporations (e.g. diet: consumption of less sugar and meat; physical activity: 
promotion of active transport in cities instead of cars, investment in green areas instead 
of real state, and promotion of a more extensive use of non-electronic activities during 
leisure time). Even better population health indicators would require a lower demand of 
healthcare professionals and pharmacological products.
The argument that technologies may help us make more sustainable healthy choices should 
be subject to scrutiny given the over simplistic approach of behavioural change behind such 
claims. For example, in a recent randomized controlled trial, the provision of one physical 
activity wearable monitor to increase weight loss by higher physical activity did not offer 
advantages compared with standard weight lost approaches without these devices9. Similarly, 
personalized nutrition advice (internet-delivered intervention) based on information on 
individual diet and lifestyle, phenotype, or genotype did not promote larger and sustained 
changes in dietary behaviour compared with non-personalized approaches (advice based 
on dietary guidelines)3. As shown in Table S3 in this study3, after six months of intervention, 
the intake of fruits, vegetables, whole grains, oily fish, red meat, low-fat dairy products, salt, 
and total energy intake did not differ between the control group and the pooled personalized 
group. Finally, evidence is growing on the fact that the communication of genetic risk of 
diseases to individuals, a fundamental basis of precision medicine12, does not lead to changes 
in health behaviours7. Taken together, the narrative that the widespread implementation of 
technology will help us change and sustain behaviours seems to be fake claims of precision 
medicine advocates. Indeed, social, cultural, environmental, and economic factors largely 
determine health-related behaviours14.
FAIR AND EGUALITARIAN SOCIETIES: HEALTHY LIVES
In summary, precision medicine seems to be a secondary route to a healthier world. 
The XXI century is becoming a turning point for life on Earth – human-made climate 
disruption, chaotic urbanization, forced migration, pollution, degradation, and depletion 
of natural resources are all examples of challenges15 for which precision medicine has little 
to offer compared to broader public health approaches. The evidence supports policies 
that address climate change and human health simultaneously, such as the promotion 
of non-motorized transport18 or the reduction of animal sourced foods in our diets (i.e., a 
study has estimated that global mortality could be reduced by 6%–10% and food-related 
greenhouse gas emissions could be reduced by 29%–70%)17. Enough scientific evidence 
shows that too much medicine is harming humans and should therefore be abandoned. 
For example, although the market has many valuable drugs, the overall balance for the 
population indicates that their dangers outweigh their benefits5 and there are good reasons 
(e.g., over-diagnosis) to rethink the widespread screening programs for cancer prevention1. 
Advocates of the precision medicine initiative neglect the limitations of person-centred, 
high-risk strategies (a reduced population health impact) and, therefore, their messages 
may be useful to dictate priorities in the research agenda (e.g., overestimating the role of 
genetics, stem cell therapies) and to justify the exorbitant healthcare expenditure in the 
current era of finance-based medicine. If societies aspire to address strong risk factors 
for non-communicable diseases8 such as smoking, poor diets, or physical inactivity, they 
will require downplaying the numerous promises of precision medicine and a greater 
appreciation of the importance of spending more resources on the foundational conditions 
that shape the health of the populations.
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